Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial
Suneet Sandhu(The University of Sydney), Stephen P. Mulligan(Royal North Shore Hospital), Giles Best(Flinders University), Paul Turner(University of Oxford), Rosemary Harrup(University of Tasmania), Juliana Di Iulio(Peter MacCallum Cancer Centre), Maya Latimer(Georgetown University), Devinder Gill(Princess Alexandra Hospital), William Renwick(The Royal Melbourne Hospital), Mathias Bressel(Peter MacCallum Cancer Centre), Naomi Mackinlay(Royal North Shore Hospital), Cecily Forsyth(Gosford Hospital), Leanne Berkahn(Auckland City Hospital), Philip Campbell(Barwon Health), Gavin Cull(Sir Charles Gairdner Hospital), David R. Simpson(North Shore Hospital), Bryone J. Kuss(Flinders Medical Centre)
Cited by 0
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
|New England Journal of Medicine|2018|429